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Background: Persistent symptoms after treatment for neuroborreliosis are common for reasons mainly unknown.
These symptoms are often unspecific and could be caused by dysfunctions in endocrine systems, an issue that has
not been previously addressed systematically. We therefore mapped hormone levels in patients with previous
confirmed Lyme neuroborreliosis of different outcomes and compared them with a healthy control group.
Methods: Twenty patients of a retrospective cohort of patients treated for definite Lyme neuroborreliosis were
recruited 2.3 to 3.7 years (median 2.7) after diagnosis, together with 23 healthy controls. Lyme neuroborreliosis
patients were stratified into two groups according to a symptom/sign score. All participants underwent
anthropometric and physiological investigation as well as an extensive biochemical endocrine investigation
including a short high-dose adrenocorticotropic hormone stimulation (Synacthen®) test. In addition to hormonal
status, we also examined electrolytes, 25-hydroxy-vitamin D and interleukin-6.
Results: Eight patients (40%) had pronounced symptoms 2-3 years after treatment. This group had a higher
cortisol response to synacthen as compared with both controls and the Lyme neuroborreliosis patients without
remaining symptoms (p < 0.001 for both comparisons). No other significant differences in the various baseline
biochemical parameters, anthropometric or physiological data could be detected across groups.
Conclusions: Apart from a positive association between the occurrence of long-lasting complaints after Lyme
neuroborreliosis and cortisol response to synacthen, no corticotropic insufficiency or other serious hormonal
dysfunction was found to be associated with remaining symptoms after treatment for Lyme neuroborreliosis.
Background
Lyme borreliosis is the most commonly reported tick-
transmitted disease in the northern hemisphere [1]. The
overall incidence in the south of Sweden has been
reported to be 69 per 100 000 inhabitants and year,
with marked regional variability. For instance, the inci-
dence in Kalmar County was reported to be 160 per 100
000 inhabitants and year [2].
Clinical manifestations of Lyme borreliosis are diverse
and include erythema migrans, neuroborreliosis, arthri-
tis, lymphocytoma, carditis, and acrodermatitis chronica
atrophicans. In Sweden, Lyme neuroborreliosis (LNB) is
the second most common manifestation after erythema
migrans. Current antibiotic treatment recommendations
for LNB comprise either doxycycline, benzyl penicillin
or ceftriaxone [1-3].
Residual symptoms after treatment of LNB are com-
mon and have been reported by some 25-50% of
patients 6-142 months after onset of neurological symp-
toms [3-5]. Residual symptoms may include arthralgia,
musculoskeletal or radicular pain, paresthesia, dysaesthe-
sia together with persistent fatigue and neurocognitive
impairment. Although there are theories regarding the
background of these persistent symptoms, the pathogen-
esis is still mainly unknown [6,7]. Early recognition and
treatment of acute LNB seems to be important in order
to reduce the risk of persistent symptoms [3].
It is well known that tuberculosis meningitis and var-
ious other infectious diseases can affect and cause dys-
function of the hypothalamus and/or the pituitary gland
[8-16]. It has also been proposed that interleukin-6 (IL-
6) may stimulate the hypothalamus-pituitary-adrenal
(HPA) axis during inflammatory stress [17], and in
healthy individuals a positive correlation between IL-6
levels and cortisol response after a standard short low-
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has been reported [18].
In a recent study, isolated corticotropic insufficiency
was noted in four of 19 patients (21%) with previous
infectious diseases of the central nervous system. The
study in fact included four patients with a history of
LNB, but no hormonal dysfunction was found in these
[19]. Endocrine dysfunctions, with general symptoms
and complaints could be one possible explanation, and
vitamin D deficiency, linked to diffuse musculoskeletal
complaints, could be another explanation for the
reported complaints after LNB [20]. Neither of these has
been thoroughly investigated in this context previously.
I nt h ep r e s e n ts t u d yw et h e r e f o r ea i m e da tm a p p i n g
patients having experienced confirmed LNB with and
without persistent symptoms and to compare them with
healthy controls regarding anthropometric data, various
hormone levels, and, in particular, the HPA axis. In
addition, we wanted to relate the high-dose ACTH sti-
mulation (Synacthen®) test-induced cortisol response to
the level of symptoms as well as to levels of IL-6.
Methods
Patients and controls
From the routine laboratory data system of the Depart-
ment of Microbiology at Kalmar County Hospital, 36
adult patients were identified as having had a positive
anti-borrelia antibody index (AI; IDEA™ Lyme Neuro-
borreliosis kit, Oxoid, Basingstoke, United Kingdom)
with purified, native Borrelia afzelii strain DK1 flagellum
as test antigen in paired cerebrospinal fluid/serum sam-
ples during 2004-2005. According to medical charts at
Kalmar County Hospital, seven of these 36 patients
were not considered suffering from ongoing LNB. These
seven patients were all considered to have other diag-
noses based on clinical history, symptoms and labora-
tory findings.
The remaining 29 patients received a clinical diagnosis
of LNB and were treated with doxycycline, in one case
together with ceftriaxone. Painful radiculitis was found
in 19, unspecific complaints in 11, cranial nerve palsy in
9 and meningitis in 2 patients. Each patient presented
with one or multiple features. An IgM or IgG AI of ≥
0.3 was considered positive according to the manufac-
turer. Positive IgM AI was found in 13/29 patients
(range 0-20.5; median 0.1), and positive IgG AI was
found in 29/29 patients (range 0.4-973.4; median 15.8).
Positive blood serological results were found in 26 of
the 29 patients (Immunetics® Quick ELISA C6 Borrelia
Assay Kit, Immunetics Inc., Cambridge, MA, USA).
Although six of these 29 patients lacked pleocytosis
(>5*10
6 leukocytes/L) of the cerebrospinal fluid, they
were still clinically diagnosed with LNB according to
medical records, based on a typical history of symptoms
and findings together with the positive AI, and were
therefore treated.
I n d i v i d u a l si nt h i sr e t r o s p e c t i v ec o h o r t ,c o n s i s t i n go f
29 patients, were informed and offered participation in
the study. Twenty of these 29 (69%) patients partici-
pated in the study during February-May 2008. One
additional patient accepted participation, but was on
medication with prednisolone due to suspected poly-
myalgia rheumatica and was therefore not included in
the study. The remaining eight patients were reminded
by letter after a couple of weeks, but no additional parti-
cipants were recruited.
In addition, a control group of healthy adult blood
donors was recruited. Only subjects with an approved
declaration of health and no history of previous Lyme
borreliosis infection and a negative borrelia serological
test (C6 Lyme ELISA™ Kit, Immunetics®, Boston, MA,
USA) were included. Controls using medications, work-
ing night shift or having had any previous hormonal dis-
ease were also not included. Finally, 23 healthy control
individuals participated in the study during February-
May 2008. The study was performed according to the
Declaration of Helsinki, and the study protocol was
reviewed and approved by the regional ethical review
board in Linköping, Sweden. All patients and controls
gave informed consent.
Study protocol and implementation
A study protocol was designed for the LNB patients in
whom 15 different neurological signs together with 25
different symptoms were addressed. Blood pressure,
heart rate, weight, length and waist measurement were
noted and fasting (minimum 8 hours) blood samples
were collected between 8 and 9 a.m. from all
participants.
Then, an intramuscular injection with 0.25 mg of
Synacthen® (Novartis Pharma AG Basel, Switzerland)
was given after which samples for cortisol were taken at
30 and 60 minutes. An experienced nurse, with access
to a physician, administered synacthen and supervised
the participants. No adverse events occurred during the
test. Directly after the injection all LNB patients were
neurologically examined and questioned by the same
physician (IT) regarding persistent, ongoing symptoms
after treatment of LNB. Only neurological signs and
symptoms related by the patient to the LNB infection
were noted. The neurological examination included sys-
tematic testing of cranial nerves, motor and sensory
functions, balance, ataxia and reflexes. All results were
noted in the study protocol, and all participants were
unaware of the other study results. Analyses were per-
formed according to methods and instruments in Addi-
tional file 1, Table S1, where reference values also are
noted. The highest of the 30 and 60 minute values of
synacthen stimulated cortisol minus baseline cortisol
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(ACI).
Statistical analysis
Differences between groups were analysed with Kruskal-
Wallis non-parametrical test, followed by Mann-Whit-
ney’s U-test in case of significance. Due to age differ-
ences between blood donors (controls) and LNB
patients, adjusting for age was made using factorial
ANOVA for the normally distributed parameters (ACI,
heart rate and systolic blood pressure) followed by Dun-
can’s test in case of significance. Pearson correlation was
used to analyse the coupling between post treatment
severity (see results) score and number of symptoms on
the one hand and ACI as well as IL-6 values (log-nor-
mally distributed, thus using the logarithm values) on
the other. A significance level of p < 0.05 was consid-
ered statistically significant. Statistica 8.0 was used for
statistical calculations.
Results
Symptoms and neurological signs
Twenty LNB patients were included in the study and
the median follow-up time from diagnosis was 2.7 years
(range 2.3 to 3.7). The most common long-lasting symp-
toms were arthralgia (40%), balance disorder (35%) and
paresthesia (35%) (Additional file 2, Table S2). In the
neurological examination, three patients were not fully
recovered after facial palsy. No other pathological neu-
rological signs were noted int h e s ep a t i e n t s .I nf o u r
patients, ataxia, disturbed motor and sensory nerve
functions were found (data not shown).
By adding the numbers of symptoms (range 0-25; in
the questionnaire) to the number of pathological signs
in the neurological examination (range 0-15; according
to the study protocol), a post treatment severity (PTS)
score was calculated for each LNB patient (range 0-40).
Based on the PTS score, patients could be divided into
two groups with more or less pronounced symptoms
after LNB. An arbitrarily chosen cut off level of four dis-
criminated the patients in two clusters (Figure 1) and
gave the most significant difference regarding ACI
across groups: Patients having a score less than four
(LNB
-, n = 12) and patients with a score above four
(LNB
+, n = 8). Based on this system, 8/20 (40%) of the
LNB patients were classified as having more pronounced
long-lasting symptoms in spite of treatment for LNB
according to recommendations [3]. The distribution of
symptoms in the LNB subgroups is also shown in Addi-
tional file 2, Table S2.
Physiological and biochemical results
Anthropometric and physiological parameters such as
body measurements, heart rate and blood pressure is
shown together with biochemical results in controls and
in the LNB
+ and LNB
- groups in Additional file 3, Table
S3. In a first step, comparisons between all three groups
were performed using Kruskal-Wallis test, showing that
age (p = 0.002), heart rate (p = 0.010), systolic blood
pressure (p = 0.011), follicle-stimulating hormone (FSH;
p = 0.033), ACI (p = 0.004) and IL-6 (p = 0.048) were
statistically different across groups. Further analyses
using Mann-Whitney’s U-test showed that controls were
younger than LNB
+ and LNB
- patients (p = 0.001 and
0.023, respectively), but no difference in age was noted
in between LNB
+ and LNB
- patients. Also, higher ACI
was found in the LNB
+ group compared to both other
groups (p = 0.002 for both comparisons), while no dif-
ferences were found regarding basal concentrations of
cortisol or metabolic parameters such as waist measure-
ment or fasting glucose. Heart rate was also found to be
higher in the LNB
+ group compared to both controls
and LNB
- groups (p = 0.004 and 0.006, respectively).
Furthermore, higher systolic blood pressure (p = 0.003)
and levels of FSH (p = 0.01) were noted in the LNB
+
group compared to controls. Concentrations of FSH in
women are dependent on time of menstruation and rise
after menopause and are therefore difficult to compare
among groups. Because of the difference in age between
groups, statistical correction for age was done. Thereby,
ACI still remained higher in the LNB
+ group compared
to both controls and the LNB
- group (p < 0.001 for
both comparisons). However, no differences between
groups were detected regarding IL-6, heart rate or systo-
lic blood pressure after age correction. Since a diagnosis
of LNB without pleocytosis has been debated, we also,
as an extra precaution, reanalysed the coupling between
PTS score and ACI as well as differences in ACI
between groups after exclusion of 4/20 LNB patients (2
LNB
+,2L N B
-) with normal CSF cell counts, with simi-
lar results.
Correlations
Correlations between PTS score and ACI (Figure 1)
showed that ACI for LNB patients was significantly cor-
related to the PTS score (r = 0.68; p = 0.001). The chosen
PTS score cut off level of four is also shown in Figure 1,
separating the LNB patients into the two subgroups. No
correlation between IL-6 and PTS score or IL-6 and ACI
was found, not even for healthy controls only (data not
shown). Finally, we also determined correlations in LNB
patients classified according to self reported symptoms
only, i.e. excluding signs in the PTS score. Still, a signifi-
cant correlation between ACI and the added number of
symptoms was found (r = 0.65; p = 0.002, data not
shown). No correlation between ACI and the number of




- patients had corticotrophin-releas-
ing hormone (CRH) levels < 1.0 pmol/L, as well as all
controls except two (1.2 and 1.9 pmol/L, respectively).
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autoimmune hypothyroidism based on increased levels
of TSH (4.3 and 11.5 mU/L) combined with a decreased
level of thyroxine in one case (6.4 pmol/L), as well as
positive levels of anti-thyroid peroxidase antibodies in
both cases.
One LNB
- patient was found to have an increased
level of ionized calcium and was after further investiga-
tion diagnosed with primary hyperparathyroidism.
Discussion
We found no significant differences regarding various
basal hormonal concentrations when comparing LNB
patients of different clinical outcomes 2-3 years post
treatment to controls. This finding is clinically relevant
in that it indicates that endocrine dysfunction is not a
major cause of long-lasting symptoms despite optimal
treatment of LNB. However, a positive correlation
between the PTS score and ACI was noted. After sub
grouping and corrections for age the LNB
+ group still
had higher ACI than the LNB
- group and healthy con-
trols, whereas no differences were found in metabolic
parameters such as waist measurement or fasting glucose.
In a recent study it was shown that ACI correlated
positively to IL-6 levels in normal subjects [18], and
therefore higher levels of IL-6 in LNB patients with
more pronounced symptoms could be expected to cor-
relate with higher ACI. Associations between IL-6 and
depression, vital exhaustion and feeling of hopelessness
have also been previously reported [21-23]. However, in
t h ep r e s e n ts t u d yw ed i dn o tf i n das i g n i f i c a n tc o r r e l a -
tion between PTS score and IL-6 or between ACI and
IL-6, not even when studying the control group only,
thereby contradicting the results of Zarkovic et al [18].
We therefore interpret the correlation between patient
score and ACI in this study as independent of IL-6
levels. It is however interesting to notice the relation
between clinical symptoms and cortisol response to
synacthen indicating adrenal hyper-responsiveness in
these patients. Some earlier studies have shown super-
sensitivity to ACTH stimulation with higher cortisol
responses in depressed patients compared to controls
[24-26], while others have been unable to differentiate
between depressed patients and healthy volunteers
[27,28]. Cortisol response to ACTH stimulation and
adrenal gland volume has also been shown to be state-
dependent with decreased cortisol response to ACTH
and decreased adrenal volume in successfully treated
depressed patients [29,30]. Although a complete evalua-
tion of depression in the LNB patients in this study was
02468 1 0 1 2 1 4 40













































Figure 1 Symptoms and neurological signs compared to absolute cortisol increment in Lyme neuroborreliosis patients post
treatment. Numbers of symptoms and neurological signs at follow up 2.3 to 3.7 years post treatment (x-axis) and absolute cortisol increment
(ACI) after 0.25 mg Synacthen® injection (y-axis) in Lyme neuroborreliosis patients (n = 20). Pearson correlation coefficient r = 0.68; p = 0.001. The
post treatment severity (PTS) score was calculated by adding the number of symptoms and pathological neurological signs strictly related to the
Lyme neuroborreliosis infection for each patient. The dotted line at score = 4 represents a chosen cut off. Patients with a score above 4 were
considered having more pronounced complaints (LNB
+ n = 8) and below four not pronounced complaints (LNB
- n = 12).
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to Additonal file 2, Table S2, were not the most com-
mon and therefore other causes for the higher ACI in
the LNB+ patients may be suspected. It has also been
reported that chronic exposure to stressful situations,
perhaps such as the persistent symptoms noted in this
s t u d y ,r e s u l t si nt o n i cc h a n g e si nt h eH P Aa x i s[ 3 1 ] .
Taken together, further investigation is necessary in
order to determine the cause of increased ACI in LNB
patients with persistent symptoms and the relation to
LNB, depression, stress signalling, cortisol and adrenal
gland volume.
In this study, as much as 8/20 (40%) of LNB patients
were considered to suffer from persistent symptoms
between 2-3 years post treatment. This is in line with
previously reported proportions (25-50%) of patients
suffering from persistent symptoms after treatment for
LNB [3-5]. The figure of 40% could however be overes-
timated in this study due to an overrepresentation of
patients with symptoms participating in the study. It can
n o tb ee x c l u d e dt h a tt h o s ee i g h tp a t i e n t st h a tc h o s et o
not participate, were patients with minor or no persis-
tent symptoms and that they therefore were less moti-
vated to participate. Six of those eight patients were
younger than 54 years of age, and may also have chosen
not to participate due to working conditions as the
whole investigation took around two hours of time. One
other weakness of this study is that controls are signifi-
cantly younger than LNB patients. This is because blood
donors served as controls, and only few blood donors
between 65-70 years of age and no donors above 70
years of age were available for participation. The differ-
ences of age between groups were therefore considered
and age correction performed in the statistical analyses
when appropriate.
Conclusion
In conclusion, this study showed that a high proportion
(40%) of LNB patients suffer from persistent symptoms
2-3 years post treatment. Although a positive correlation
between ACI and PTS score was found in the LNB
group, no major differences regarding various basal hor-
mone levels could be detected comparing the LNB sub-
groups and the control group. This finding indicates
that endocrine dysfunction is not a major cause for
long-lasting post-treatment symptoms in LNB.
Additional file 1: Analyses, reference values, methods and instruments
used.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
20-S1.PDF]
Additional file 2: Symptoms in Lyme neuroborreliosis patients 2-3
years post treatment. Persistent subjective symptoms in patients
related to Lyme neuroborreliosis 2.3 to 3.7 years post treatment
according to questionnaire (n = 20).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2334-10-
20-S2.PDF]
Additional file 3: Anthropometric, physiological and biochemical
parameters in controls and Lyme neuroborreliosis patients 2-3
years post treatment. Anthropometric, physiological and biochemical
parameters in healthy controls (n = 23) and Lyme neuroborreliosis
patients without (LNB
- n = 12) or with (LNB
+ n = 8) pronounced
symptoms and neurological signs at follow up 2.3 to 3.7 years post
treatment. After correction for age, absolute cortisol increment remained
significantly higher in the LNB
+ group compared to both controls and
the LNB
- group (p < 0.001).
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